• Our Company
    • Our Company
      • Therapeutics
      • Precision Medicine
      • MedTech
      • Telix Manufacturing Solutions
    • Our Technology
    • Partnering with Telix
    • Board & Management
    • Sustainability
  • Our Portfolio and Pipeline
    • Disease Areas
      • Urologic Oncology
      • Neurologic Oncology
      • Other Tumors
    • Our Pipeline
    • Our Portfolio
    • Research & Development
  • Clinical Trials
  • Investor Centre
  • News & Views
  • Careers
    • Careers
    • Find a Job
  • Our Company
    • Our Company
      • Therapeutics
      • Precision Medicine
      • MedTech
      • Telix Manufacturing Solutions
    • Our Technology
    • Partnering with Telix
    • Board & Management
    • Sustainability
  • Our Portfolio and Pipeline
    • Disease Areas
      • Urologic Oncology
      • Neurologic Oncology
      • Other Tumors
    • Our Pipeline
    • Our Portfolio
    • Research & Development
  • Clinical Trials
  • Investor Centre
  • News & Views
  • Careers
    • Careers
    • Find a Job
Home News & Views

News & Views

FILTER:
All ASX BD&AM Clinical Events News Scientific Publication Uncategorized

Telix at ANZSNM Annual Scientific Meeting 2022

Telix is a title partner of the 52nd Australian and New Zealand Society of Nuclear Medicine (ANZSNM) Annual Scientific Meeting (ASM) being held this week in Brisbane, Queensland, 13-15 May.
Read more

2nd Joint Telix and Duchembio Symposium – Clinical Utility of PSMA PET Imaging in Prostate Cancer and Key PSMA PET Image Interpretation for Urologists

On World Theranostics Day, with our partner, Duchembio, we are pleased to present the 2nd joint symposium on the clinical utility of PSMA-PET in prostate cancer imaging and key PSMA PET image interpretation for urologists in Korea.
Read more

New Video Series “PSMA PET/CT TODAY” Discusses the Future of Prostate Cancer Care with Leading Experts

Telix is pleased to announce the launch of PSMA PET/CT Today, a five-part video series, featuring leading theranostics experts, on the role of advanced diagnostic imaging in prostate cancer care.
Read more

TRALA Study of TLX66 in AL-Amyloidosis Presented at ASH 2021

Telix is pleased to announce the first peer-reviewed results from the Phase I/IIa TRALA (Targeted Radiotherapy for AL Amyloidosis) study of the Company’s bone marrow conditioning investigational candidate TLX66 (90Y-besilesomab) in patients with Systemic Amyloid Light Chain Amyloidosis (AL-Amyloidosis), presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition.
Read more

First Telix and Duchembio Joint Symposium – Emergence of PSMA-PET Imaging in South Korea

With our partner, Duchembio, we are pleased to present a first joint symposium on 68Ga-PSMA-PET prostate cancer imaging in Korea.
Read more

ZIRCON Presentation at International Kidney Cancer Symposium 2021

Telix is pleased to release a poster on the Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab), the Company’s investigational imaging agent for clear cell renal cell carcinoma (ccRCC) with positron emission tomography (PET), presented at the International Kidney Cancer Symposium (IKCS) 2021, organized by the Kidney Cancer Association.
Read more

Telix Japan – Upcoming Events in November

We are pleased to announce Telix’s participation at three major industry events in Japan during November 2021.
Read more

IPAX-1 Late Breaking Oral Presentation at the Congress of Neurological Surgeons (CNS) Meeting

Telix presented the IPAX-1 study of TLX101 in glioblastoma at the Congress of Neurological Surgeons Annual Meeting
Read more

Telix Satellite Symposium at European Association of Nuclear Medicine Annual Congress 2021

Telix is pleased to announce a satellite symposium at the 34th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held from 20-23 October 2021.
Read more

Telix at AdMeTech Summit on Precision Diagnosis and Treatment of Prostate Cancer

Telix is delighted to announce our support for the AdMeTech 5th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer, to be held virtually from 23-25 September 2021.
Read more
Previous page 1 … 4 5 6 7 8 Next page
  • Our Company
  • Our Portfolio
  • Investor Center
  • News & Views
  • Careers
  • Contact Us
  • Legal Notices

Subscribe to our newsletter to stay in the loop

© Telix Pharmaceuticals Limited. 55 Flemington Road, North Melbourne, VIC 3051, Australia.​
The Telix Pharmaceuticals, the Illuccix and Gozellix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.​
This website is intended for corporate communication purposes only and is not intended as promotion or advertising to any audience in any country worldwide.​

  • Privacy Policy
  • Terms of Use
  • Cookies Policy
  • Consumer Health Privacy Notice
  • Privacy Settings

Subscribe

* indicates required

By subscribing, you are agreeing to the terms of our Global Privacy Policy and provide consent to receive updates from Telix”